AMAG Pharmaceuticals Book/Share
What is the Book/Share of AMAG Pharmaceuticals?
The Book/Share of AMAG Pharmaceuticals, Inc. is 8.24
What is the definition of Book/Share?
Book value per share is a company’s assets minus liabilities divided by the number of shares outstanding.
mrq (most recent quarter)
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Book/Share of companies in the Health Care sector on NASDAQ compared to AMAG Pharmaceuticals
What does AMAG Pharmaceuticals do?
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.
Companies with book/share similar to AMAG Pharmaceuticals
- Powerleader Science & Technology has Book/Share of 8.22
- BlackRock MuniVest Fund, Inc has Book/Share of 8.22
- Tootsie Roll Industries has Book/Share of 8.23
- Howmet Aerospace has Book/Share of 8.23
- Prudential plc has Book/Share of 8.24
- KE has Book/Share of 8.24
- AMAG Pharmaceuticals has Book/Share of 8.24
- Li Auto has Book/Share of 8.24
- SUEZ SA has Book/Share of 8.24
- Yuexiu Transport Infrastructure has Book/Share of 8.25
- Weiye has Book/Share of 8.25
- Tata Sponge Iron has Book/Share of 8.25
- Mayne Pharma has Book/Share of 8.25